Fatty Liver and Diabetes: A Hidden Link

The relationship between fatty liver disease and type 2 diabetes is among the most consequential bidirectional relationships in modern medicine. The conditions occur together so frequently that they are often described not as separate diseases but as different manifestations of the same underlying metabolic dysfunction. Patients with type 2 diabetes have fatty liver disease at rates approaching 70 to 80 percent. Patients with fatty liver disease have type 2 diabetes or pre-diabetes at similarly elevated rates. The shared underlying mechanisms involving insulin resistance, hyperinsulinemia, and various other metabolic disturbances explain why these conditions cluster.

The bidirectional nature of the relationship has substantial clinical implications. Diabetes worsens fatty liver disease, accelerating progression toward NASH, fibrosis, and cirrhosis. Fatty liver disease worsens diabetes, increasing insulin resistance, complicating glycemic control, and potentially affecting development of diabetes complications. The mutual worsening means that addressing one condition supports the other, while neglecting either undermines management of both. The integrated nature of these conditions argues for integrated approaches to care.

The mechanisms linking the conditions reflect specific biological processes. Insulin resistance, the central feature of type 2 diabetes, drives fat accumulation in the liver through multiple pathways. Excess insulin, the consequence of insulin resistance, stimulates fat synthesis in the liver. Various hormonal and inflammatory factors contribute to both conditions. The shared mechanisms mean that interventions targeting one often help the other.

The clinical importance has grown as understanding has advanced. Patients with both conditions face elevated risks across multiple domains. Cardiovascular disease, the leading cause of death in patients with either condition, is particularly elevated when both are present. Liver complications including cirrhosis and hepatocellular carcinoma are more common in diabetic patients with fatty liver disease. Diabetes complications including kidney disease, retinopathy, and neuropathy may be affected by liver disease. The combination of these elevated risks supports the importance of recognizing and managing both conditions when they coexist.

This article examines the connection between fatty liver disease and diabetes. It explains how the conditions are linked, identifies the mechanisms, discusses implications for patients with both, examines treatment approaches, and frames the broader picture. The understanding supports informed engagement with care for these connected conditions.

For broader context on fatty liver disease, see What Is Fatty Liver Disease (NAFLD)?.

⸻

How the Conditions Are Linked

Several specific aspects characterize the connection between fatty liver disease and diabetes.

Prevalence

The prevalence of each condition in patients with the other is substantial. In patients with type 2 diabetes, fatty liver disease prevalence is approximately 70 to 80 percent, substantially higher than in the general population. In patients with fatty liver disease, type 2 diabetes prevalence is approximately 20 to 30 percent, with additional patients having pre-diabetes or undiagnosed diabetes. The high overlap reflects shared underlying mechanisms.

Bidirectional Relationship

The conditions affect each other in both directions. Patients with diabetes are at substantially higher risk of developing fatty liver disease, as the metabolic disturbances of diabetes drive liver fat accumulation. Patients with fatty liver disease are at substantially higher risk of developing diabetes, as the metabolic disturbances associated with fatty liver disease promote insulin resistance and eventual diabetes.

Worsening of Each Other

Each condition can worsen the other. Diabetes worsens fatty liver disease through accelerated progression, with patients having both conditions showing higher rates of NASH (steatohepatitis), fibrosis, and cirrhosis than patients with fatty liver disease alone. Fatty liver disease worsens diabetes through increased insulin resistance, more difficult glycemic control, and various other effects. The mutual worsening means that effective management requires addressing both conditions.

Shared Mechanisms

The shared mechanisms reflect deep biological connections rather than coincidental cooccurrence. Insulin resistance, hyperinsulinemia, chronic inflammation, altered hormones, and various other factors connect the conditions.

For more on the disease spectrum, see Stages of Fatty Liver Disease.

⸻

Mechanisms Connecting the Conditions

Several specific mechanisms link fatty liver disease and diabetes.

Insulin Resistance

Insulin resistance is the central mechanism connecting the conditions. In insulin resistance, cells throughout the body become less responsive to insulin's effects. The pancreas compensates by producing more insulin, producing the elevated insulin levels that characterize the condition. The elevated insulin promotes fat synthesis in the liver through stimulation of de novo lipogenesis (fat production from carbohydrate substrates). The insulin resistance also affects fat metabolism in ways that promote liver fat accumulation. The combination of these effects substantially contributes to fatty liver disease in patients with diabetes.

Hyperinsulinemia

Hyperinsulinemia (elevated insulin levels) directly stimulates liver fat synthesis and contributes to other metabolic effects. The hyperinsulinemia precedes the development of overt diabetes in many patients, contributing to fatty liver disease before diabetes is diagnosed.

Increased Fat Delivery

Increased delivery of fatty acids to the liver from adipose tissue and dietary sources provides substrate for fat accumulation. The increased fat delivery is partly driven by insulin resistance affecting normal regulation of fat release from adipose tissue.

Chronic Inflammation

Chronic low-grade inflammation associated with both diabetes and fatty liver disease contributes to disease progression. Inflammatory cytokines including TNF-alpha, IL-6, and various others affect liver metabolism and insulin signaling.

Altered Adipokines

Adipose tissue, particularly visceral fat, releases various adipokines that affect metabolism. Adiponectin, an anti-inflammatory adipokine that improves insulin sensitivity, is decreased in both conditions. Leptin and various other adipokines have complex effects.

Beta Cell Dysfunction

In type 2 diabetes, pancreatic beta cell dysfunction develops over time. The dysfunction reduces insulin production and contributes to hyperglycemia. Some research suggests that fatty liver disease may directly affect beta cell function through various mechanisms, contributing to diabetes progression.

Gut Microbiome Effects

The gut microbiome differs between healthy individuals and those with both conditions. The differences affect production of various metabolites with implications for both conditions.

For more on lean NAFLD, see Fatty Liver and Obesity: What's the Connection?.

⸻

Implications for Patients

The connection between fatty liver disease and diabetes has several specific implications.

Elevated Disease Severity

Patients with both conditions tend to have more severe disease than those with either alone. Fatty liver disease in diabetic patients tends to progress faster, with higher rates of NASH and fibrosis. Diabetes in patients with fatty liver disease tends to be more difficult to control, with higher rates of complications.

Cardiovascular Risk

Cardiovascular risk is substantially elevated in patients with both conditions. The combined effects of the metabolic disturbances drive accelerated atherosclerosis. Cardiovascular disease is the leading cause of death in patients with either fatty liver disease or diabetes, and the combination further elevates risk.

Liver Cancer Risk

Hepatocellular carcinoma risk is elevated in diabetic patients with fatty liver disease. The combination contributes to the substantial rise in NAFLD-related liver cancer.

Diabetes Complications

Whether fatty liver disease affects development of diabetes complications including kidney disease, retinopathy, and neuropathy is an area of active research. The relationships are complex.

Mortality

Overall mortality is elevated in patients with both conditions compared to those with either alone.

For more on reversal, see Can Fatty Liver Be Reversed?.

⸻

Screening and Diagnosis

Identification of both conditions in patients with one warrants attention.

Screening Diabetic Patients for Fatty Liver Disease

Patients with diabetes warrant consideration of fatty liver disease evaluation given the high prevalence. Liver function tests are often performed routinely in diabetic patients. Elevated tests warrant further evaluation. Imaging including ultrasound or MRI can identify fatty liver disease. Various non-invasive fibrosis assessments including FIB-4 score, NAFLD Fibrosis Score, and FibroScan support evaluation of disease severity.

Screening Patients With Fatty Liver Disease for Diabetes

Patients with fatty liver disease warrant evaluation for diabetes given the high prevalence. Hemoglobin A1c testing identifies diabetes and pre-diabetes. Fasting glucose and oral glucose tolerance tests provide additional information.

Identifying Both Conditions Early

Early identification of both conditions supports timely intervention. Patients identified before substantial damage develops have better outcomes than those identified at advanced stages.

Cardiovascular Risk Assessment

Cardiovascular risk assessment is particularly important in patients with both conditions. Various risk calculators and assessment approaches guide management.

For more on diagnosis broadly, see How Fatty Liver Disease Is Diagnosed.

⸻

Treatment Approaches

Treatment of patients with both conditions addresses the shared mechanisms.

Weight Loss

Weight loss benefits both conditions. The weight loss addresses the insulin resistance underlying both, with corresponding improvements in liver fat, glycemic control, and various other parameters. Specific targets correlate with specific outcomes:

• Loss of 3 to 5 percent of body weight produces measurable improvements.
• Loss of 7 to 10 percent typically produces substantial improvements.
• Loss of 10 percent or more may improve fibrosis in addition to other parameters.

Dietary Modifications

Dietary modifications that support both conditions include several elements:

• The Mediterranean dietary pattern has demonstrated benefits for both fatty liver disease and diabetes.
• Reducing refined carbohydrates and added sugars particularly benefits both conditions.
• Adequate fiber supports both glycemic control and liver health.

Physical Activity

Physical activity benefits both conditions through multiple mechanisms. Recommendations include at least 150 minutes per week of moderate aerobic activity plus muscle-strengthening activities. Both aerobic and resistance exercise contribute.

For more on exercise specifically, see Best Exercise for Fatty Liver Disease.

Specific Medications

Several medication classes benefit both conditions:

• GLP-1 receptor agonists including semaglutide and tirzepatide produce substantial improvements in both diabetes and fatty liver disease. The medications are increasingly used as foundational therapy when both conditions are present.
• SGLT2 inhibitors produce benefits in both conditions, though typically more modest in fatty liver disease than GLP-1 agonists.
• Pioglitazone has demonstrated benefits in NASH and improves glycemic control. Side effects including weight gain and fluid retention affect use.
• Metformin remains widely used for diabetes but has limited direct effect on fatty liver disease beyond what its glycemic effects produce.

Various other diabetes medications have different specific effects on fatty liver disease.

Specific Fatty Liver Disease Medications

Resmetirom, the first FDA-approved medication specifically for fatty liver disease (approved 2024), is for NASH with significant fibrosis. The medication can be used in patients with diabetes. Vitamin E has shown benefits in some studies of NASH.

Cardiovascular Risk Management

Cardiovascular risk management with statins, blood pressure control, and various other approaches addresses the elevated cardiovascular risk in patients with both conditions. Statins are safe in fatty liver disease and may have specific benefits.

Bariatric Surgery

Bariatric surgery for patients with severe obesity produces dramatic improvements in both conditions. The procedures are appropriate for patients meeting specific criteria.

For more on alcohol-related distinction, see Alcohol vs Non-Alcoholic Fatty Liver Disease.

⸻

Specific Diabetes Medications and Fatty Liver Disease

Different diabetes medications have different effects on fatty liver disease.

GLP-1 Receptor Agonists

GLP-1 receptor agonists have emerged as among the most useful medications for patients with both conditions. Semaglutide produces substantial weight loss and improvements in NASH including fibrosis improvements in some patients, with multiple clinical trials demonstrating benefits. Tirzepatide, a dual agonist of GLP-1 and GIP receptors, produces even greater weight loss with corresponding metabolic benefits. Other GLP-1 agonists including liraglutide and dulaglutide have similar but generally less potent effects. The medications are appropriate for patients with type 2 diabetes who would benefit from improvements in both conditions.

SGLT2 Inhibitors

SGLT2 inhibitors including empagliflozin, dapagliflozin, and various others produce modest benefits in fatty liver disease along with their diabetes and cardiovascular benefits. The medications work through different mechanisms than GLP-1 agonists.

Pioglitazone

Pioglitazone has demonstrated benefits in NASH including improvements in inflammation and fibrosis. Side effects including weight gain, fluid retention, and various others affect use. The benefits in NASH must be weighed against these side effects.

Metformin

Metformin remains the typical first-line diabetes medication. Direct effects on fatty liver disease beyond what its glycemic effects produce are limited.

Insulin

Insulin therapy may be needed for some diabetic patients but does not directly improve fatty liver disease. Insulin can promote weight gain that may affect fatty liver disease.

DPP-4 Inhibitors

DPP-4 inhibitors have limited specific effects on fatty liver disease.

For more on related considerations, see Most Commonly Misdiagnosed Conditions.

⸻

Special Patient Populations

Several specific populations have particular considerations.

Patients With Newly Diagnosed Diabetes

Patients with newly diagnosed diabetes warrant evaluation for fatty liver disease given the high prevalence. Early identification supports comprehensive management.

Patients With Pre-Diabetes

Patients with pre-diabetes (impaired glucose tolerance or impaired fasting glucose) face elevated fatty liver disease risk. Aggressive intervention can prevent progression to diabetes.

Patients With Long-Standing Diabetes

Patients with long-standing diabetes may have advanced fatty liver disease. Comprehensive evaluation including fibrosis assessment guides management.

Patients With Type 1 Diabetes

Type 1 diabetes is also associated with fatty liver disease, though through somewhat different mechanisms. Patients with type 1 diabetes who develop obesity or various other risk factors face elevated risk.

Patients With Diabetic Complications

Patients with diabetic complications including kidney disease face complex management situations. Various medication choices may need adjustment.

Older Adults

Older adults with both conditions benefit from comprehensive management adapted to their specific situations.

Pregnant Women

Pregnancy in women with both conditions warrants specialized care addressing both maternal and fetal considerations.

⸻

Common Misconceptions

Several misconceptions about the diabetes-fatty liver connection deserve attention.

Misconception: Only Some Diabetics Get Fatty Liver Disease

The substantial majority of patients with type 2 diabetes have fatty liver disease. The conditions are tightly linked.

Misconception: Fatty Liver Disease Just Reflects Diabetes

While the conditions share mechanisms, fatty liver disease can have specific consequences and warrants attention beyond just diabetes management.

Misconception: Treating Diabetes Will Cure Fatty Liver Disease

Diabetes management helps fatty liver disease but may not be sufficient alone. Specific attention to fatty liver disease may be needed.

Misconception: Both Conditions Always Progress Together

The conditions can progress at different rates in individual patients. Ongoing assessment of both is important.

Misconception: Only Type 2 Diabetes Connects to Fatty Liver Disease

Type 1 diabetes can also be associated with fatty liver disease, particularly with obesity or various other risk factors.

Misconception: Once Diabetes Is Controlled, Fatty Liver Disease Will Resolve

Glycemic control helps but may not fully resolve fatty liver disease. Continued attention to both conditions supports best outcomes.

Misconception: Fatty Liver Disease Doesn't Affect Diabetes Outcomes

Fatty liver disease may affect cardiovascular outcomes, complications, and various other aspects of diabetes management.

⸻

Prevention

Prevention strategies address both conditions simultaneously.

Maintaining Healthy Weight

Maintaining healthy weight reduces risk of both conditions.

Healthy Eating Patterns

Healthy eating patterns reduce risk of both conditions. The Mediterranean dietary pattern has demonstrated benefits.

Regular Physical Activity

Regular physical activity supports prevention of both conditions.

Limiting Alcohol

Limiting alcohol supports liver health and may affect diabetes risk.

Sleep

Adequate sleep supports metabolic health.

Regular Healthcare Engagement

Regular healthcare engagement supports identification of risk factors and early intervention.

Family History Awareness

Awareness of family history of either condition supports informed prevention efforts.

⸻

When to See a Specialist

Several types of specialists may be involved in care. Primary care providers manage many patients with both conditions. Endocrinologists evaluate patients with diabetes, particularly complex cases. Hepatologists evaluate patients with significant fatty liver disease. Cardiologists may be involved for cardiovascular risk management. Registered dietitians provide essential dietary guidance. For complex situations, evaluation at major medical centers with comprehensive metabolic disease programs provides access to specialized expertise.

⸻

Conclusion

Fatty liver disease and type 2 diabetes are closely connected conditions sharing underlying mechanisms involving insulin resistance, hyperinsulinemia, chronic inflammation, and various other metabolic disturbances. The conditions occur together so frequently that they are often described as different manifestations of the same underlying metabolic dysfunction.

Approximately 70 to 80 percent of patients with type 2 diabetes have fatty liver disease. Approximately 20 to 30 percent of fatty liver disease patients have diabetes, with additional patients having pre-diabetes or undiagnosed diabetes.

The bidirectional relationship means each condition worsens the other. Diabetes accelerates fatty liver disease progression. Fatty liver disease worsens diabetes through increased insulin resistance and various other effects. The mutual worsening argues for integrated management.

Mechanisms connecting the conditions include insulin resistance, hyperinsulinemia, increased fat delivery to the liver, chronic inflammation, altered adipokines, beta cell dysfunction, and gut microbiome effects.

Implications include elevated disease severity, substantially elevated cardiovascular risk, elevated liver cancer risk, possible effects on diabetes complications, and elevated overall mortality.

Screening considerations support evaluation of fatty liver disease in diabetic patients and evaluation of diabetes in fatty liver disease patients. Both conditions benefit from early identification.

Treatment approaches address shared mechanisms. Weight loss benefits both. Dietary modifications including the Mediterranean pattern, reduced refined carbohydrates, and adequate fiber support both conditions. Physical activity benefits both. Specific medications including GLP-1 receptor agonists (particularly impactful), SGLT2 inhibitors, pioglitazone, and resmetirom (newly approved for NASH) address various aspects. Cardiovascular risk management is essential. Bariatric surgery produces dramatic improvements in both conditions for patients with severe obesity.

Different diabetes medications have different effects on fatty liver disease. GLP-1 receptor agonists have emerged as particularly useful for patients with both conditions. SGLT2 inhibitors and pioglitazone also have specific benefits.

Various special populations including patients with newly diagnosed diabetes, pre-diabetes, long-standing diabetes, type 1 diabetes, diabetic complications, older adults, and pregnant women all have specific considerations.

The encouraging element is that addressing the shared underlying mechanisms produces benefits for both conditions. The combination of weight loss, lifestyle modifications, and increasingly available medications targeting both conditions produces good outcomes for most patients.

For most patients with both conditions, the practical messages are clear. The conditions are deeply linked through shared mechanisms. Comprehensive care addressing both produces better outcomes than approaches focused on only one. Available treatments increasingly target both conditions effectively. The combination of patient engagement with comprehensive care provides the foundation for the best possible outcomes for these connected conditions.

⸻

Medical Disclaimer

This content is for informational purposes only and does not constitute medical advice. Individuals should consult a qualified healthcare provider for diagnosis and treatment.